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DCs are major APCs and can direct host im-
mune responses toward either immunity or 
tolerance (Banchereau and Steinman, 1998; 
Steinman et al., 2003). As immune controllers, 
DCs can deliver differential signals to other im-
mune cells through intercellular interactions 
and soluble factors (Banchereau and Steinman, 
1998; Rissoan et al., 1999; Akira et al., 2001; 
Soares et al., 2007), resulting in different qual-
ity and quantity of host immune responses. In 
addition, different subsets of DCs display com-
mon and unique biological functions for con-
trolling host immune responses (Caux et al., 
1996; Maldonado-López et al., 1999; Pulendran 
et al., 1999; Banchereau et al., 2000; Shortman 
and Liu, 2002; Dudziak et al., 2007; Soares 
et al., 2007; Klechevsky et al., 2008).
DCs express pattern recognition receptors 
(Figdor et al., 2002; Geijtenbeek et al., 2004; 
Brown, 2006), most notably represented by 
Toll-like receptors (Akira et al., 2001) and 
lectinlike receptors (LLRs; Figdor et al., 2002; 
Geijtenbeek et al., 2004; Brown, 2006; Caparrós 
et al., 2006). Ligation of TLRs results in 
the activation of DCs, followed by cytokine 
and chemokine secretion that contribute to the 
outcomes of host immune responses. LLRs 
operate as constituents of the powerful anti-
gen capture and uptake system (Delneste et al., 
2002; Figdor et al., 2002; Geijtenbeek et al., 
2004; Brown, 2006; Geijtenbeek and Gringhuis, 
2009). Recent compelling evidence also 
indicates that individual LLRs expressed on 
DCs might possess unique functions (Delneste 
et al., 2002; Figdor et al., 2002; Brown, 2006; 
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Dendritic cells (DCs) can initiate and shape host immune responses toward either immunity or 
tolerance by their effects on antigen-specific CD4+ T cells. DC-asialoglycoprotein receptor  
(DC-ASGPR), a lectinlike receptor, is a known scavenger receptor. Here, we report that targeting 
antigens to human DCs via DC-ASGPR, but not lectin-like oxidized-LDL receptor, Dectin-1, or  
DC-specific ICAM-3–grabbing nonintegrin favors the generation of antigen-specific suppressive 
CD4+ T cells that produce interleukin 10 (IL-10). These findings apply to both self- and foreign 
antigens, as well as memory and naive CD4+ T cells. The generation of such IL-10–producing CD4+ 
T cells requires p38/extracellular signal-regulated kinase phosphorylation and IL-10 induction  
in DCs. We further demonstrate that immunization of nonhuman primates with antigens fused  
to anti–DC-ASGPR monoclonal antibody generates antigen-specific CD4+ T cells that produce  
IL-10 in vivo. This study provides a new strategy for the establishment of antigen-specific IL-10–
producing suppressive T cells in vivo by targeting whole protein antigens to DCs via DC-ASGPR.
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activation motiflike motif (Valladeau et al., 2001), but the 
biological function of DC-ASGPR expressed on DCs has not 
been characterized. In this study, we demonstrate for the first 
time that DC-ASGPR has a novel function for generating 
antigen-specific IL-10–producing suppressive CD4+ T cells 
in vitro. Furthermore, antigens fused to anti–DC-ASGPR 
antibody can generate IL-10–producing antigen-specific T cells 
in macaques. This study provides a novel strategy for the 
establishment of antigen-specific IL-10–producing regula-
tory T cells in vivo.
RESULTS
DCs express LOX-1 and DC-ASGPR
mAbs to human LOX-1 and DC-ASGPR were generated. 
Both anti–LOX-1 (IgG2a: clone 15C4) and anti–DC-ASGPR 
(IgG2a, clone 49C11) mAb bound to blood myeloid DCs 
(mDCs; LinHLA-DR+CD11c+CD123), CD14+ mono-
cytes, and CD19+ B cells, but not plasmacytoid DCs 
(pDCs; LinHLA-DR+CD11cCD123+) or CD3+ T cells in 
peripheral blood mononuclear cells (PBMCs; Fig. 1 A). 
The entire population of monocyte-derived DCs cultured 
in vitro with GM-CSF and IL-4 (IL-4DCs) expressed both 
LOX-1 and DC-ASGPR in a similar level. IFNDCs gener-
ated with GM-CSF and IFN- expressed slightly higher lev-
els of both lectins than IL-4DCs did (Fig. 1 B). The specificity 
of mAbs was confirmed by staining 293F cells transfected 
with LOX-1 and DC-ASGPR expres-
sion vectors (unpublished data).
Human skin sections were stained 
with anti–LOX-1 and anti–DC-ASGPR 
mAbs. Confocal images show that 
both LOX-1 and DC-ASGPR are ex-
pressed mainly in the cells in dermis 
(Fig. 1, C and D). Approximately 50 
and 70% of dermal CD1c+ DCs 
(CD1c+HLA-DR+) expressed LOX-1 
and DC-ASGPR, respectively (Fig. 1 E). 
Geijtenbeek and Gringhuis, 2009), that can contribute to 
shaping the quality and quantity of host immune responses. 
For example, lectinlike oxidized-LDL receptor (LOX-1), 
Dectin-1, and DC-specific ICAM-3–grabbing nonintegrin 
(DC-SIGN) are capable of delivering intracellular signals, 
either by themselves or by combination with TLRs, that ac-
tivate DCs and can result in altered T cell responses (Figdor 
et al., 2002; Delneste et al., 2002; Geijtenbeek et al., 2004; 
Smits et al., 2005; Brown, 2006; Caparrós et al., 2006; Dillon 
et al., 2006; Geijtenbeek and Gringhuis, 2009; Geurtsen 
et al., 2009). Certain features of LLRs—antigen capture, 
uptake, and signaling capacity—place them as key immune 
receptors that could determine the outcomes of host immune 
responses. Indeed, DCs activated via Dectin-1 result in polar-
ized Th17 CD4+ T cell responses (LeibundGut-Landmann 
et al., 2007; Gringhuis et al., 2009). It was also reported that 
signals via Dectin-1 induce IL-10 in DCs (Rogers et al., 
2005; Ni et al., 2010), and activation of DCs via Dectin-1 
and TLR2 results in regulatory T cell responses (Dillon et al., 
2006). DC-SIGN binding by different pathogens can lead to 
promotion of Th2 responses (Bergman et al., 2004; Caparrós 
et al., 2006; Geurtsen et al., 2009) and the induction of regu-
latory T cell differentiation (Smits et al., 2005; Geijtenbeek and 
Gringhuis, 2009).
DC-asialoglycoprotein receptor (DC-ASGPR) is a scav-
enger receptor carrying an immunoreceptor tyrosine-based 
Figure 1. DCs express LOX-1 and DC-
ASGPR. (A) Expression of LOX-1 (top) and  
DC-ASGPR (bottom) on the surface of blood 
myeloid DCs (mDCs; LinHLA-DR+CD11c+CD123), 
plasmacytoid DCs (pDCs; LinHLA-
DR+CD11cCD123+), CD14+ monocytes, CD19+ 
B cells, and CD3+ T cells. (B) Expression of 
LOX-1 (top) and DC-ASGPR (bottom) on the 
surface of monocyte-derived IFNDCs and  
IL-4DCs. Representative data from experi-
ments using cells from six healthy donors 
are presented in A and B. Immunofluores-
cent staining of healthy human skin sections 
with DAPI, -HLA-DR, -CD1c and -LOX-1 
mAb (C), or -DC-ASGPR (D) labeled  
with fluorescents. (E) Summary of data 
generated with skins from two healthy  
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IL-10, but lower amounts of IFN- and IL-2 when com-
pared with those expanded with anti–LOX-1-HA1 (Fig. 2 A). 
This increased amount of IL-10 was caused by the enhanced 
expansion of IL-10–producing CD4+ T cells (Fig. 2 B). 
CD4+ T cells expanded with either anti–DC-ASGPR-HA1 
or anti–LOX-1-HA1 secreted low amounts of IL-4 and IL-5 
(<20 pg/ml). We further confirmed at a single-cell level 
that anti–DC-ASGPR-HA1 resulted in greater numbers of 
IL-10–producing, but lower numbers of IFN-–, TNF-, and 
IL-2–producing HA1-specific CD4+ T cells compared with 
those expanded with anti–LOX-1-HA1 (Fig. S3 A). In the 
same experiment, we also tested the frequency of HA1-
specific CD4+ T cells expanded by DCs loaded with HA1 
peptide pool. Fig. S3 (A and B) shows that peptide pool was 
less efficient than anti–DC-ASGPR-HA1 and anti–LOX-1-
HA1 at expanding IL-10– and IFN-–producing HA1-
specific CD4+ T cells, respectively. Peptide pool alone did 
not result in significant numbers of either TNF+ or IL-2+ 
CD4+ T cell responses after 7 d of culture (unpublished data). 
However, we observed that DCs loaded with combina-
tions of peptide pools and anti–DC-ASGPR resulted in en-
hanced HA1-specific IL-10–producing CD4+ T cell responses 
(Fig. S3 C). Conversely, combinations of peptide pools 
and anti–LOX-1 resulted in enhanced IFN-–producing 
CD4+ T cell responses. Neither IL-4– nor IL-5–producing 
HA1-specific CD4+ T cells were detected. DCs loaded with 
either anti–DC-ASGPR or anti–LOX-1 mAb alone did not 
result in HA1- or PSA-specific CD4+ T cell responses 
(unpublished data).
These enhanced IL-10 responses were also observed 
when PSA was delivered to either IFNDCs (Fig. 2, C and D) 
or blood mDCs (Fig. 2, E and F) via DC-ASGPR. Conversely, 
PSA-specific CD4+ T cells induced with anti–LOX-1-
PSA secreted higher IFN- levels than those induced with 
anti–DC-ASGPR-PSA (Fig. 2, C and E). In the same ex-
periment, DCs loaded with PSA peptide pool did not result 
in significant numbers of IL-10–producing PSA-specific 
CD4+ T cells (unpublished data). Neither HA1-specific 
(Fig. 2 G, top left) nor PSA-specific IL-10–producing CD4+ 
T cells elicited by IFNDCs loaded with anti–DC-ASGPR 
constructs (Fig. 2 G, top right) expressed Foxp3. However, 
>60% of IL-10–producing CD4+ T cells elicited with anti–
DC-ASGPR constructs expressed CTLA-4. A small frac-
tion (30%) of them also expressed PD-1. IL-10–producing 
CD4+ T cells expanded with anti–LOX-1 constructs did 
not express Foxp3 either (Fig. 2 G, bottom left). Fig. 2 H 
shows that the majority of IL-10–producing CD4+ T cells 
also expressed IFN- when stimulated with PMA/ionomycin, 
suggesting their Th1 origin (Macián et al., 2002; Saraiva 
et al., 2009). Fig. S4 (A and B) further demonstrates that 
targeting HA1 and PSA to DCs via DC-ASGPR result 
in enhanced HA1- (Fig. S4 A) and PSA-specific (Fig. S4 B) 
IL-10–producing CD4+ T cell responses when compared 
with targeting antigens to DCs via LOX-1. Collectively, 
we conclude that both foreign (HA1) and self-antigens 
(PSA) delivered to DCs via DC-ASGPR generate higher 
Detailed data for the expression of LOX-1 and DC-ASGPR in 
human skin sections are presented in Fig. S1. Neither DC-
ASGPR nor LOX-1 was expressed on the surface of BDCA3+ 
DCs in the blood of healthy donors (unpublished data).
Antigens delivered to DCs via DC-ASGPR or LOX-1 result  
in antigen-specific CD4+ T cell responses
Recombinant mAbs carrying mouse variable region chimeras 
with human  chain and human IgG4 carrying two site muta-
tions (S228P and L235E; Reddy et al., 2000) were made, and 
then fused to hemagglutinin 1 (HA1 subunit of influenza virus 
A/PR/8/34, H1N1; anti–LOX-1-HA1, anti–DC-ASGPR-
HA1, and control IgG4-HA1) and prostate-specific antigen 
(PSA; anti–LOX-1-PSA, anti–DC-ASGPR-PSA, and control 
IgG4-PSA; Fig. S2 A). Binding assays show that both anti–
LOX-1-HA1 and anti–DC-ASGPR-HA1 bind to DCs in simi-
lar levels, and the binding was greater than with IgG4-HA1 
(Fig. S2 B). Anti–LOX-1-PSA and anti–DC-ASGPR-PSA also 
bound to DCs greater than IgG4-PSA (Fig. S2 C). DCs loaded 
with 1 µg/ml anti–LOX-1-HA1 or anti–DC-ASGPR-HA1 in-
duced similar, but greater CD4+ T cell proliferation than did DCs 
loaded with IgG4-HA1 or unloaded-DCs (Fig. S2 D). Anti–
LOX-1-PSA and anti–DC-ASGPR-PSA also induced greater 
naive CD4+ T cell proliferation than did IgG4-PSA (Fig. S2 E). 
Although both anti–LOX-1 and anti–DC-ASGPR constructs 
were more efficient than control IgG4 constructs at inducing 
CD4+ T cell proliferation, the level of CD4+ T cell proliferation 
was variable in different experiments. This was largely dependent 
on the numbers of T cells in the culture, maturation stages of 
monocyte-derived IFNDCs, amounts of recombinant constructs 
loaded to DCs, and cells from different healthy donors. Collec-
tively, our data demonstrate that antigens (HA1 as a foreign antigen 
and PSA as a self-antigen) delivered to DCs via DC-ASGPR and 
LOX-1 resulted in enhanced CD4+ T cell responses.
To test the ability of recombinant fusion proteins to direct 
antigen-specific CD4+ T cell responses, CD4+ T cells expanded 
with anti–DC-ASGPR-HA1 and anti–LOX-1-HA1 were re-
stimulated at day 7 with clusters of HA1 peptides for measur-
ing intracellular IFN- expression (Fig. S2 F). Individual 
peptides in cluster 4 that had been selected as stimulating maxi-
mal IFN- expression were further tested, and three peptides, 
HA1250-266, HA1256-272, and HA1262-278, were selected (Fig. S2 
G). HA1280-296 was used as a control. In the same experiment, 
DCs loaded with 1 µg/ml IgG4-HA1 did not result in sig-
nificant numbers of HA1-specific CD4+ T cell responses 
(unpublished data). The frequency of total HA1-specific IFN-
–expressing CD4+ T cells in the blood was 0.4% of total 
CD4+ T cells (Fig. S2 H). Thus, our data demonstrate that tar-
geting HA1 to DCs via LOX-1 or DC-ASGPR is an efficient 
way to expand HA1-specific CD4+ T cells, although not all the 
proliferating cells are HA1-specific CD4+ T cells.
DC-ASGPR favors the generation of IL-10–producing  
CD4+ T cells
We observed that HA1250-266-specific CD4+ T cells expanded 
with anti–DC-ASGPR-HA1 secreted greater amounts of 
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Functional specialization of DC-ASGPR for the generation 
of IL-10–producing CD4+ T cells
Both Dectin-1 and DC-SIGN can contribute to the en-
hanced regulatory T cell responses (Smits et al., 2005; Dillon 
et al., 2006; Geijtenbeek and Gringhuis, 2009) in the pres-
ence of signals via other TLRs and in the models using 
IL-10–producing, but lower IFN-–producing CD4+ T cell 
responses than did the same antigens delivered to DCs via 
LOX-1. In addition, targeting antigens to DCs via DC-ASGPR 
and LOX-1 is far more efficient than loading antigen-derived 
peptide pools to DCs at eliciting antigen-specific CD4+  
T cell responses.
Figure 2. Antigen targeting to DCs via DC-ASGPR favors the generation of antigen-specific IL-10–producing CD4+ T cells. IFNDCs (5 × 103) 
were loaded with 1 µg/ml -DC-ASGPR-HA1 or -LOX-1-HA1, and then co-cultured with CFSE-labeled autologous total CD4+ T cells (1–2 × 105) for 7 d. 
(A) CD4+ T cells were restimulated with peptide HA1250-266 for 48h, and cytokine levels in the culture supernatants were measured. Each line represents 
the data from a single experiment. P-values were tested by Student’s t test. (B) CD4+ T cells were restimulated with indicated peptides and stained for 
intracellular IL-10. HA1280-296 is a negative control. Peptides tested in B had been selected in Fig. S2 (F and G). Four independent experiments showed simi-
lar results. (C) Naive CD4+ T cells (1–2 × 105) were co-cultured with IFNDCs (5 × 103) loaded with 1 µg/ml recombinant fusion proteins for 7 d. CD4+  
T cells were restimulated with peptides indicated for 48 h. IL-10 and IFN- levels in culture supernatants were assessed. Error bars represent mean ± SEM 
of triplicate assay. Three independent experiments with 59 PSA-derived peptides showed similar results. (D) Frequency of PSA-specific IL-10–producing 
CD4+ T cells elicited by recombinant fusion proteins. Four independent experiments showed similar results. (E) Experiments in C were performed with 
blood mDCs (LinHLA-DR+CD11c+CD123). (F) Experiments in D were performed with blood mDCs. In both E and F, two independent experiments showed 
similar results. (G) Expression levels of Foxp3, PD-1, and CTLA-4 on HA1250-266-specific (left) and PSA30-44-specific CD4+ T cells producing IL-10 (right).  
(H) After 7 d of co-culture of purified naive CD4+ T cells and DCs loaded with either -LOX-1-PSA or -DC-ASGPR-PSA, CD4+ T cells were stained for 
intracellular IFN- and IL-10 during restimulation with 50 ng/ml PMA and 1 µg/ml ionomycin. Three independent experiments showed similar results (G and H).
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IFN-–producing CD4+ T cell responses, although this needs 
to be further studied. CD4+ T cells induced with anti–LOX-
1-PSA also secreted the greatest amount of IL-2 and TNF. 
Similar to the HA1-specific CD4+ T cell responses (Fig. S3), 
targeting PSA to DCs via LOX-1, DC-SIGN, or Dectin-1 are 
more efficient than loading PSA peptide pool to DCs at in-
ducing IFN-–producing CD4+ T cell responses. In addition, 
CD4+ T cells induced with PSA peptide pool or any of those 
recombinant construct did not secrete significant amounts 
of IL-4 or IL-5 (unpublished data). Most notably, anti–DC-
ASGPR-PSA resulted in the greatest level of IL-10–producing 
PSA-specific CD4+ T cell responses. Thus, we conclude that 
DC-ASGPR possesses a specialized function for generating 
antigen-specific IL-10–producing CD4+ T cells.
Upon loading with anti–DC-ASGPR-HA1, DCs were 
more efficient than monocytes and B cells in generating 
IL-10–producing CD4+ T cells (Fig. S5, A and B). DCs were 
also more potent than monocytes or B cells in expanding 
IFN-–producing CD4+ T cells when they were loaded 
with anti–LOX-1-HA1 (Fig. S5, C and D). HA1- and PSA-
derived peptides characterized in this study and their cor-
responding HLA class II types are summarized in Table S1. 
The majority of HA1- and PSA-derived peptides in Table S1 
have not been previously described. Thus, targeting antigens 
to DCs is an efficient way to elicit high magnitudes and broad 
repertoires of antigen-specific CD4+ T cells.
Suppressive function  
of IL-10–producing CD4+ T cells
We next tested the suppressive func-
tion of IL-10–producing CD4+ T cells 
generated with anti–DC-ASGPR con-
structs in both allogeneic and autologous 
systems. Differentiated Qtracker 565low 
CD4+ T cells were sorted from co-
cultures of autologous naive T cells 
and IFNDCs loaded with anti–DC-
ASGPR-PSA or anti–LOX-1-PSA, 
and then re-stained with Qtracker 565. 
CFSE-labeled allogeneic naive CD4+ 
T cells (responders) were mixed with 
increasing numbers of the Qtracker 
pathogens. Thus, we tested whether Dectin-1 and DC-SIGN 
could also favor the generation of IL-10–producing CD4+  
T cells. Anti–Dectin-1 (clone 15E2; Ni et al., 2010) and 
anti–DC-SIGN mAbs (IgG2a: clone 16E7) were gener-
ated. Recombinant anti–Dectin-1 and anti–DC-SIGN mAbs 
were fused to PSA as for anti–DC-ASGPR-PSA and anti–
LOX-1-PSA. Both anti–Dectin-1-PSA and anti–DC-SIGN-
PSA bound to DC surface, similar to anti–DC-ASGPR-PSA 
(unpublished data). DCs were loaded with 1 µg/ml PSA 
fusion proteins or pooled PSA-derived peptides (total 59 
peptides of 15-mers overlapping 11 aa, 10 µM), and then in-
cubated with autologous naive CD4+ T cells for 7 d. CD4+ 
T cells were restimulated with PSA-derived peptides (PSA102-116 
or PSA82-96 as a control peptide), which were preselected by 
testing peptide clusters and individual peptides in the se-
lected clusters. We observed that CD4+ T cells induced with 
anti–DC-ASGPR-PSA secreted greater amounts of IL-10, 
but less IFN-, TNF, and IL-2 when compared with those 
induced with anti–LOX-1-PSA, anti–Dectin-1-PSA, and 
anti–DC-SIGN-PSA (Fig. 3). The amount of IFN- secreted 
from CD4+ T cells induced with anti–DC-ASGPR-PSA was 
comparable to that secreted from CD4+ T cells induced with 
peptide pool. However, anti–DC-ASGPR-PSA was more 
efficient than PSA peptide pool at inducing PSA-specific 
IL-10–producing CD4+ T cell responses. Interestingly, 
anti–LOX-1-PSA was more efficient than others at inducing 
Figure 3. DC-ASGPR ligation generates 
antigen-specific IL-10–producing CD4+  
T cells. IFNDCs (5 × 103) were loaded with  
1 µg/ml recombinant fusion proteins of PSA, 
pooled peptides (10 µM), or none overnight. 
CFSE-labeled autologous naive CD4+ T cells 
(1–2 × 105) were co-cultured with primed DCs 
for 7 d. CD4+ T cells were restimulated with  
1 µM PSA102-116. After 48 h, IL-10, IFN-, TNF, 
and IL-2 in the culture supernatants were 
assessed. Each dot represents the data from 
independent experiments. P-values were cal-
culated by Student’s t test.
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was significantly recovered by the addition of anti–IL-10 and 
anti–IL-10R antibodies (Fig. 5 B, top). In addition, neutral-
izing IL-10 secreted from effector CD4+ T cells induced with 
anti–DC-ASGPR-HA1 resulted in enhanced IFN-, IL-2, 
and TNF expression by HA1250-266-specific CD4+ T cells 
(Fig. 5 C, top). Summarized data from independent ex-
periments are summarized in Fig. 5 C (bottom). Collectively, 
we conclude that CD4+ T cells generated with anti–DC-
ASGPR-HA1 can suppress proliferation as well as cytokine, 
IFN-, IL-2, and TNF expression in responding cells. This 
suppression was largely dependent on IL-10 secreted by 
effector cells.
Mechanisms of DC-ASGPR–mediated generation  
of antigen-specific IL-10–producing CD4+ T cells
IL-12 (Saraiva et al., 2009), IL-10 (Barrat et al., 2002; Groux 
et al., 1997), inducible T cell co-stimulator ligand (ICOSL; Ito 
et al., 2007), and IL-27 (Awasthi et al., 2007) are known to 
contribute to the generation of IL-10–producing CD4+ T cells. 
Interestingly, DCs loaded with anti–DC-ASGPR-PSA, but 
not IgG4-PSA or anti–LOX-1-PSA, secreted IL-10 (Fig. 6 A). 
This IL-10 induction was dependent on anti–DC-ASGPR 
mAb (Fig. S6 A) and inhibited by MEK inhibitor (PD0325901), 
which inhibits extracellular signal-regulated kinase (ERK) 
565+CD4+ T cells (effectors), and then co-cultured with 
anti–DC-ASGPR-PSA–loaded IFNDCs for 5 d. Prolifera-
tion of responders was assessed by measuring CFSE dilution. 
The CD4+ T cells induced with anti–DC-ASGPR-PSA, but 
not those induced with anti–LOX-1-PSA, significantly in-
hibited proliferation of responders, and this was dependent on 
the numbers of effector cells (Fig. 4 A, top). Neutralizing 
IL-10 partially reverted the inhibition of naive allogeneic 
CD4+ T cell proliferation (Fig. 4 A, middle). Exogenous IL-10 
(100 pg/ml) added to the co-cultures resulted in significantly 
decreased proliferation of allogeneic CD4+ T cells (Fig. 4 A, 
bottom). Data from three experiments repeated in Fig. 4 A 
are summarized in Fig. 4 B. Collectively, IL-10 secreted 
from effector CD4+ T cells induced with anti–DC-ASGPR-
PSA is mainly responsible for the inhibition of allogeneic 
CD4+ T cell proliferation.
The suppressive function of these IL-10–producing CD4+ 
T cells was also confirmed in an autologous system using 
trans-well plates (Fig. 5 A). CD4+ T cells generated with 
anti–DC-ASGPR-HA1 (Fig. 5 B, top) were more efficient 
(60 and 40% at 1:1 and 1:8 effector/responder ratios, 
respectively) than those generated with anti–LOX-1-HA1 
(Fig. 5 B, bottom) at inhibiting autologous CD4+ T cell prolif-
eration. The inhibition of autologous CD4+ T cell proliferation 
Figure 4. CD4+ T cells generated with -DC-ASGPR-PSA suppress allogeneic naive CD4+ T cell proliferation in an IL-10–dependent manner. 
(A) IFNDCs were loaded with 1 µg/ml -DC-ASGPR-PSA or -LOX-1-PSA, and then co-cultured with Qtracker 565–labeled purified autologous naive CD4+ 
T cells for 7 d. Qtracker 565low CD4+ T cells were sorted as effector cells. Different numbers of effector cells were added into co-cultures of autologous 
DCs (5 × 103) loaded with 1 µg/ml -DC-ASGPR-PSA and newly purified CFSE-labeled allogeneic naive CD4+ T cells as responders (105). Proliferation of 
allogeneic CD4+ T cells was assessed by measuring CFSE dilution. Two independent experiments with triplicate assay were performed in the presence and 
absence of 10 µg/ml –IL-10/IL-10R antibodies or 100 pg/ml IL-10. (B) Summarized data from three independent experiments. Error bars represent SD. 
Statistical significance was tested by ANOVA.
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but not IFN-– or IL-2-producing CD4+ T cell responses 
(not depicted). Conversely, exogenous IL-10 added to the 
co-culture of anti–LOX-1-PSA-loaded DCs and naive CD4+  
T cells could enhance PSA-specific IL-10–producing CD4+  
T cell responses (Fig. 6 E). We also confirmed that IL-10 induc-
tion in DCs is mediated by anti–DC-ASGPR mAb (Fig. S6 A). 
In addition, DCs loaded with combinations of PSA peptide pool 
and anti–DC-ASGPR mAb can induce IL-10–producing CD4+ 
T cell responses, although anti–DC-ASGPR-PSA was more 
efficient than combinations of PSA peptide pool and anti–
DC-ASGPR mAb (Fig. S6 B). Furthermore, Fig. S6 C demon-
strates that anti–DC-ASGPR-HA1 could prevail over 
anti–LOX-1-HA1 to elicit IL-10– and IFN-–producing HA1-
specific CD4+ T cell responses. It is also important to note that 
naive CD4+ T cells co-cultured with DCs loaded with anti–
DC-ASGPR-PSA do not express IL-10 unless they are re-
stimulated with PSA-derived peptides. This rules out the 
contribution of autocrine IL-10 production by T cells in the in-
duction of IL-10–producing CD4+ T cells. We also demon-
strate that the outcomes of antigen targeting to DC-ASGPR or 
LOX-1 using our recombinant mAbs were not significantly 
affected by Fc receptors expressed on DCs (Fig. S7). Collec-
tively, we conclude that anti–DC-ASGPR mAb induces 
activation, and p38 inhibitor (SB203580; Fig. 6 A). In parallel, 
DCs exposed to anti–DC-ASGPR-PSA displayed enhanced 
phosphorylation of ERK and p38 (Fig. 6 B). Anti–DC-
ASGPR-PSA did not induce IL-12, IL-27, or ICOSL expres-
sion (unpublished data).
To test the role of IL-10 secreted from DCs in the induction 
of IL-10–producing antigen-specific CD4+ T cells, DCs were 
first treated with either the MEK inhibitor or p38 inhibitor, 
and residual inhibitors were washed out. DCs were then loaded 
with either anti–DC-ASGPR-PSA or anti–LOX-1-PSA, and 
then co-cultured with naive CD4+ T cells for 7 d. Treatment of 
DCs with the inhibitors resulted in significantly decreased IL-10 
secretion from CD4+ T cells induced with anti–DC-ASGPR-
PSA (Fig. 6 C, left). Treatment of DCs with MEK inhibitor re-
sulted in slightly decreased IL-2 secretion from CD4+ T cells 
induced with anti–LOX-1-PSA, but p38 inhibitor did not sig-
nificantly alter cytokine secretion (Fig. 6 C, right). Thus, the 
decreased IL-10–producing CD4+ T cell responses by the inhibi-
tors are not caused by the general reduction of CD4+ T cell 
responses induced by anti–DC-ASGPR-PSA. Indeed, blocking 
IL-10 in co-cultures of naive CD4+ T cells and DCs loaded with 
anti–DC-ASGPR-PSA resulted in a significantly decreased 
PSA-specific IL-10–producing CD4+ T cell responses (Fig. 6 D), 
Figure 5. CD4+ T cells generated with -DC-ASGPR-HA1 suppress HA1-specific IFN-–, TNF-, and IL-2–producing CD4+ T cell responses. 
(A) Experimental scheme for B and C. (B) FACS-sorted CFSElow effector cells generated with -DC-ASGPR-HA1 (top) or –LOX-1-HA1 (bottom) were co-
cultured with IFNDCs (5 × 103) loaded with HA1250-266 in the upper wells. Newly purified and CFSE-labeled CD4+ T cells (1–2 × 105) and IFNDCs (5 × 103) 
loaded with –LOX-1-HA1 were co-cultured in the lower wells of trans-well plates. On day 6, proliferation of CD4+ T cells in the lower wells were  
assessed by measuring CFSE dilution. –IL-10/IL-10R or control IgG was added. Statistical significance was tested by ANOVA. Three independent experi-
ments showed similar results. Error bars represent SD. (C) Frequency of IFN-–, TNF-, and IL-2–expressing CD4+ T cells was measured. Each dot in lower 
panels represents data from independent experiments. P-values were acquired by Student’s t test.
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cynomolgus macaques (Fig. 7 A). All animals (total 12 ani-
mals: 6 animals per group) were preimmunized with live 
influenza viruses (H1N1, PR8). Sera from all animals dis-
played HA1-specific IgG (unpublished data). 4 mo after 
priming, animals were immunized i.d. with either anti–
LOX-1-HA1 (right arm) and anti–LOX-1-PSA (left arm), 
or anti–DC-ASGPR-HA1 (right arm) and anti–DC-ASGPR-
PSA (left arm). After three immunizations at 40-d intervals 
with the same recombinant fusion proteins, blood was col-
lected as indicated in Fig. 7, B and C. PBMCs from animals 
immunized with anti–DC-ASGPR-HA1 secreted higher 
levels of IL-10 in response to the HA1 peptide pool when 
ERK/p38-phosphorylation and IL-10 expression in DCs, which 
contribute to the induction of antigen-specific IL-10–producing 
CD4+ T cells.
In vivo establishment of antigen-specific IL-10–producing 
CD4+ T cells
We next assessed whether the anti–DC-ASGPR–based 
constructs would induce high IL-10–producing antigen-
specific CD4+ T cells in vivo using nonhuman primates. 
DC-ASGPR is not expressed in mouse. As observed with 
human DCs, both anti–LOX-1 and anti–DC-ASGPR 
mAbs bound to CD11c+ and CD14+ cells in PBMCs of 
Figure 6. DC-ASGPR ligation induces IL-10 from DCs dependent on ERK/p38 contributing to the generation of antigen-specific IL-10–
producing CD4+ T cells. (A) IFNDCs (105) were incubated with indicated inhibitors for 1 h, washed, and loaded with 1 µg/ml IgG4-PSA, -LOX-1-PSA, or 
-DC-ASGPR-PSA. After 24 h, culture supernatants were harvested and IL-10 production was assessed. Error bars indicate the mean ± SEM of two inde-
pendent experiments with triplicate assay. (B) After 15 min of loading IFNDCs with 1 µg/ml recombinant proteins, -DC-ASGPR-PSA, or -LOX-1-PSA, 
cells were stained with indicated antibodies. Representative data from four independent experiments are presented. (C) 5 × 103 IFNDCs were treated with 
2.5 µM PD0325901 (MEK inhibitor) or SB203580 (p38 inhibitor) for 1 h and washed thoroughly. DCs were loaded with 1 µg/ml -DC-ASGPR-PSA or  
-LOX-1-PSA. CFSE-labeled autologous naive CD4+ T cells (1–2 × 105) were co-cultured for 7 d. CD4+ T cells were then restimulated with 1 µM PSA30-44 
for 48 h. IL-10, IFN-, and IL-2 in culture supernatants were assessed. Each dot represents the data generated with a single experiment. Background val-
ues acquired with control peptide (PSA82-96) were substracted. (D) Purified naive CD4+ T cells (1–2 × 105) were co-cultured with -DC-ASGPR-PSA–loaded 
IFNDCs in the presence of control IgG or –IL-10/IL-10R antibodies for 7 d. Cells were then restimulated with indicated peptides (1 µM) and stained for 
intracellular IL-10. Summary of the data from four independent experiments are presented on the right. (E) Naive CD4+ T cells (1–2 × 105) were co- 
cultured for 7 d with IFNDCs (5 × 103) loaded with 1 µg/ml -LOX-1-PSA in the presence or absence of 20 pg/ml IL-10. Cells were then restimulated with 
indicated peptides (1 µM) and stained for intracellular IL-10. Summary of the data from five independent experiments are presented in right panel.  
P-values were calculated with Student’s t test.
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DCs induce and control immune responses. The complexity 
of DC-mediated regulation of host immune responses has 
been mainly explained by the functional plasticity driven 
by external stimuli, as well as by the presence of different 
subsets of DCs. In this study, we demonstrated that DC-
ASGPR expressed on DCs has a novel function to generate 
antigen-specific IL-10–producing CD4+ T cells both in vitro 
and in vivo.
DC-ASGPR was first cloned by Valladeau et al. (2001), 
and it has been known as a scavenger receptor. We further 
demonstrate that DC-ASGPR can deliver intracellular sig-
nals to activate DCs. As results of activation, DCs secrete 
IL-10 and chemokines (MCP-1 and MIP-1; unpublished 
data). DC-ASGPR–mediated IL-10 induction in DCs re-
quires ERK/p38 phosphorylation (Saraiva et al., 2009). 
This IL-10 contributes to the generation of IL-10–produc-
ing CD4+ T cells, as previously described (Groux et al., 
1997; Barrat et al., 2002). Furthermore, differences in IL-10 
production by DCs correlate with ERK activation (Kaiser 
et al., 2009). Ligation of DC-ASGPR did not induce IL-12, 
compared with those immunized with anti–LOX-1-HA1 
(Fig. 7 B, top). Conversely, PBMCs from animals immu-
nized with anti–LOX-1-HA1 secreted significantly higher 
levels of IFN- than animals immunized with anti–DC-
ASGPR-HA1 (Fig. 7 B, bottom). The same findings were 
made with animals that were primed and boosted twice 
with PSA fusion proteins. PSA-specific IL-10–producing 
cellular responses were preferentially mounted in animals 
immunized with anti–DC-ASGPR-PSA (Fig. 7 C, top). 
Consistent with our in vitro data (Figs. 2 and 3), animals 
immunized with anti–LOX-1-PSA mounted higher PSA-
specific IFN-–producing cellular responses than animals 
immunized with anti–DC-ASGPR-PSA (Fig. 7 C, bottom). 
For both HA1 and PSA, the peak of IL-10–producing cel-
lular responses was obtained at week one, but the peak of 
IFN-–producing cellular responses was obtained at week 
three. Levels of IL-10 and IFN- secreted from Staphylo-
coccal enterotoxin B–stimulated PBMCs are presented in 
Fig. 7 D. Collectively, targeting antigens to in vivo DCs via 
DC-ASGPR can establish antigen-specific IL-10–producing 
T cells in vivo.
Figure 7. Immunization with -DC-ASGPR-HA1 and -DC-ASGPR-PSA generates antigen-specific IL-10–producing T cell responses in 
nonhuman primates. (A) Expression levels of LOX-1 and DC-ASGPR in PBMCs of cynomolgus macaques. (B and C) 12 animals primed and boosted i.d. 
with live influenza viruses (H1N1, A/PR8/38) were divided into two groups (6 animals/group). One group of animals was immunized i.d. with 250 µg   
-LOX-1-HA1 (right arm) and 250 µg -LOX-1-PSA (left arm). The other group was immunized i.d. with 250 µg -DC-ASGPR-HA1 (right arm) and 250 µg 
-DC-ASGPR-PSA (left arm). After the second boosting with the recombinant fusion proteins, PBMCs (2 × 105 cells/200 µl of medium/well in 96-well 
plates) were restimulated with 25 µM peptide pools of HA1 (B) or PSA (C), respectively. Cytokines in the culture supernatants were measured by ELISA. 
Peptide pools of HIVgag were controls. Values presented in B and D are after substraction of control values. Statistical significance was tested by ANOVA. 
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et al., 2001; Barrat et al., 2002; Roncarolo and Battaglia, 
2007). A minute amount of IL-10 secreted by regulatory 
T cells can efficiently suppress proliferation and IFN- ex-
pression by responding cells. To further determine whether 
those IL-10–producing cells were from Th1, cells were re-
stimulated with PMA/ionomycin; our data showed that the 
majority of IL-10–producing cells can also express IFN- 
(Macián et al., 2002; Saraiva et al., 2009). IL-10–producing 
CD4+ T cells of Th1 origin plays crucial roles in limiting host 
immune pathology (Jankovic et al., 2007; O’Garra and Vieira, 
2007; Roncarolo and Battaglia, 2007; Trinchieri, 2007; 
Gabrysová et al., 2009).
The nature of cytokines produced by CD4+ T cells is a 
crucial element that directs the quantity and quality of im-
mune responses. IL-10–producing CD4+ T cells are major 
effectors limiting immune pathology in autoimmune and 
inflammatory diseases (Moore et al., 2001; Anderson et al., 
2007; Jankovic et al., 2007; Roncarolo and Battaglia, 2007; 
Trinchieri, 2007; Gabrysová et al., 2009; Häringer et al., 
2009; Saraiva and O’Garra, 2010). Administration of IL-10 
in clinical trials has so far shown limited efficacy (Moore 
et al., 2001; Schreiber et al., 2000; Baumgart and Sandborn, 
2007). Although immunizations of soluble antigens have 
been shown to induce IL-10 in mouse in vivo models 
(Gabrysová et al., 2009), their use in human disease is lim-
ited as result of potential induction of inflammatory effector 
cytokines with deleterious side effects, which led to inter-
ruption of such trials for multiple sclerosis (MS; Kappos 
et al., 2000). Recent studies have demonstrated that in vitro 
expanded regulatory T cells, particularly alloantigen-specific 
regulatory T cells (Sagoo et al., 2011), have clinical efficacy 
at preventing graft rejection in humanized mice (Feng et al., 
2011; Sagoo et al., 2011). However, adoptive transfer of in 
vitro–generated regulatory T cells has not been successful 
yet in patients (Roncarolo and Battaglia, 2007). Thus, a 
strategy for in vivo establishment of IL-10–producing antigen-
specific CD4+ T cells has long been demanded for the man-
agement of such diseases. This study provides a new concept 
for the establishment of antigen-specific IL-10–producing 
regulatory T cells in vivo by targeting whole protein anti-
gens to DCs via DC-ASGPR. Furthermore, DC-ASGPR ap-
pears to be a universal target for designing vaccines against 
autoimmune diseases where autoantigens are well defined, 
such as type 1 diabetes and multiple sclerosis. Therapeutic 
efficacy of such vaccines needs to be tested in clinical trials. 
Beyond the ability of generating antigen-specific regulatory 
T cells, IL-10 produced through anti–DC-ASGPR engage-
ment may be expected to have potential positive effects on 
antigen-specific antibody production, and this will need to 
be examined carefully in future studies.
MATERIALS AND METHODS
Cells. Monocyte-derived DCs, IFNDCs, and IL-4DCs, were generated as 
previously described (Rogers et al., 2005; Ni et al., 2010). Total CD4+  
T cells were purified using CD4+  T cell enrichment kits (StemCell) and 
naive CD4+ T cells (CD45RA+CD45RO; purity > 99.8%) from healthy 
male donors were sorted by FACSAria (BD). Naive CD4+ T cells were used for 
IL-27, or ICOSL expression in DCs. We have previously 
described that ligation of Dectin-1 with anti–Dectin-1 mAb 
delivers signals through Syk and induces human DCs to se-
crete significant amount of IL-10, as well as IL-1 and IL-6 
(Ni et al., 2010). However, activation of DCs via Dectin-1 
did not result in polarized IL-10–producing CD4+ T cell 
responses. Indeed, DCs activated via Dectin-1 result in po-
larized Th17 responses (LeibundGut-Landmann et al., 2007; 
Saijo et al., 2007; Gringhuis et al., 2009). Cross-linking of 
DC-SIGN with anti–DC-SIGN mAbs or anti–DC-SIGN 
fusion proteins was able to activate DCs only when DCs 
were co-activated with TLR2 ligands, resulting in MIP-1 
and minimal level of IL-10 secretion (unpublished data). 
Subsequently, DCs loaded with anti–DC-SIGN fusion pro-
teins did not favor the generation of IL-10–producing 
CD4+ T cells. Thus, the altered T cell responses (Bergman 
et al., 2004; Caparrós et al., 2006; Geurtsen et al., 2009) by 
pathogens recognized by DC-SIGN may not be solely de-
pendent on signal via DC-SIGN. Pathogens and pathogen-
derived components could also bind to and trigger other 
receptors that are not yet characterized. In support of this, 
signals via DC-SIGN induce IL-10 only when DCs are ac-
tivated via DC-SIGN in the presence of other Toll-like re-
ceptor– or cytokine-mediated signals (Caparrós et al., 2006; 
Gringhuis et al., 2007; Geurtsen et al., 2009). Notably, tar-
geting antigens to DCs via LOX-1 resulted in significantly 
greater level of IFN-–producing CD4+ T cell responses 
than loading peptide antigens to DC or targeting the same 
antigens to DCs via any other molecule tested in this study. 
Collectively, we conclude that DC-ASGPR possesses a 
unique function that favors immune responses toward IL-10–
producing regulatory CD4+ T cell responses. Our data rep-
resent a new biological function for DC-ASGPR to induce 
antigen-specific IL-10–producing CD4+ T cells. In addi-
tion, our data show that individual LLRs expressed on DCs 
possess both common and unique functions that contrib-
ute to host immune responses in different ways. Thus, it 
is now possible to postulate that delivering antigens to 
the same type of DCs, but via different LLRs, can evoke 
different quantity and quality of antigen-specific CD4+  
T cell responses.
Delivering both self- (PSA) and foreign antigens (HA1) 
to DCs via DC-ASGPR results in antigen-specific IL-10–
producing CD4+ T cell responses. In addition, antigens de-
livered to DCs via DC-ASGPR could polarize both naive 
and memory CD4+ T cells toward IL-10–producing suppres-
sive cells. The majority of HA1-specific CD4+ T cell re-
sponses observed in this study were caused by the activation 
of preexisting memory CD4+ T cells. Although fractions of 
both PSA- and HA1-specific IL-10–producing CD4+ T cells 
expressed CTLA-4 and PD-1 to a lesser extent, suppressive 
function of those effector cells were mainly dependent on 
IL-10. IL-10–mediated suppression of CD4+ T cell prolifera-
tion and IFN- expression did not require large numbers of 
IL-10–secreting effector cells, a finding in line with previous 
studies (Bacchetta et al., 1994; Groux et al., 1997; Levings 
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T cells. Mixtures of different ratios of effectors and responders were co-cultured 
with DCs loaded with 1 µg/ml anti–DC-ASGPR-PSA in the presence of 
10 µg/ml anti–IL-10/IL-10R antibodies, 10 µg/ml control antibodies, or 100 
pg/ml IL-10 for 5 d. Proliferation of responding cells was measured by CFSE 
dilution. Trans-well plates (Nunc) were used in autologous HA1-specific sup-
pression assays. CFSElow CD4+ T cells (effectors) were sorted from co-cultures 
of total CD4+ T cells and IFNDCs loaded with anti–DC-ASGPR-HA1 or 
anti–LOX-1-HA1. Effectors in upper wells were activated with DCs loaded 
with 1–5 µM HA1-derived peptides. Newly purified and CFSE-labeled 
CD4+ T cells (responders) were co-cultured with IFNDCs loaded with anti–
LOX-1-HA1 in lower wells. Anti–IL-10 and anti–IL-10R antibodies were 
added into lower wells.
Phospho-flow cytometry. IFNDCs were loaded with 1 µg/ml recombi-
nant fusion proteins in PBS for 15 min at 37°C. Cells were stained with 
primary antibody, rabbit anti-phospho-ERK, or anti-phospho-p38 mitogen-
activated protein kinase antibodies (Cell Signaling Technology), and then 
stained with fluorescently labeled goat anti–rabbit IgG (Sigma-Aldrich).
Immunofluorescent staining of human skins. Human abdominal skins 
were obtained from healthy donors who underwent cosmetic surgeries at Baylor 
University Medical Center, according to Institutional Review Board guidelines. 
Cryosections were fixed in cold acetone, dried, and blocked for nonspecific 
fluorescence with Fc Receptor Block and Background Buster (Innovex). Sec-
tions were incubated in either anti–LOX-1, anti–DC-ASGPR, or isotype anti-
bodies labeled with Alexa Fluor 568 (Invitrogen). After blocking with normal 
mouse serum, sections were stained with anti–CD1c-Alexa Fluor 647, anti–
HLA-DR-FITC, and then subsequently stained with DAPI (Invitrogen). Digi-
tal images were taken using an Olympus BX51 with a Planapo20/0.7 or 
Planapo40/0.95 objective, a Roper Coolsnap HQ camera and Metamorph soft-
ware (Molecular Devices). Images were acquired using the same exposures for 
antibody and isotype staining and identical scaling was applied. Confocal images 
were taken with the Leica SP1 and Planapo63/1.32 objective.
Animals and immunization. 12 male cynomolgus macaques (Macaca fas-
cicularis), weighing 3–6 kg, were maintained and handled in accordance with 
European guidelines for nonhuman primate care (EEC Directive N 86–609, 
November 24, 1986). All work related to animals was in compliance with 
Institutional Review Board protocols approved by the Institute of Emerging 
Diseases and Innovative Therapies, Commissariat á l’Energie Atomique. 
Animals were primed and boosted i.d. with 107 PFU live influenza viruses, 
and then divided into 2 groups (6 animals/group). One group was immu-
nized and boosted twice i.d. with 250 µg/dose anti–LOX-1-HA1 (right 
arm) and anti–LOX-1-PSA (left arm). Another group was immunized i.d. 
with 250 µg/dose anti–DC-ASGPR-HA1 (right arm) and anti–DC-ASGPR-
PSA (left arm). Boosting was performed at every 5–6 wk after each immuni-
zation. After the second boosting with recombinant vaccines, PBMCs were 
isolated from blood using Percoll gradients (GE Healthcare). PBMCs were 
then restimulated with 25 µM peptide pools of PSA and HA1, respectively, 
and supernatant was harvested after 36 and 72 h to measure the levels of 
IFN- and IL-10, respectively, using ELISA kits (U-CyTech).
Statistical analysis. Bar graphs represent mean ± SD. Significance of dif-
ference between experimental variables was determined using the Student’s 
t test and analysis of variance (ANOVA).
Online supplemental material. Fig. S1 shows that human skin dermal 
DCs express DC-ASGPR and LOX-1. Fig. S2 shows that antigen target-
ing to DCs via DC-ASGPR or LOX-1 results in antigen-specific CD4+ 
T cell responses. Fig. S3 demonstrates that combinations of HA1 peptide 
pool and anti–DC-ASGPR or anti–LOX-1 mAb are more efficient than 
HA1 peptide pool alone, but less efficient than anti–DC-ASGPR-HA1 and 
anti–LOX-1-HA1 at eliciting HA1-specific IL-10– and IFN-–producing 
CD4+ T cell responses, respectively. Fig. S4 demonstrates that both HA1 
and PSA delivered to DCs via DC-ASGPR results in enhanced HA1- and 
PSA-specific IL-10–producing CD4+ T cell responses. Fig. S5 shows that 
assessing PSA-specific T cell responses. Total CD4+ T cells were used for 
testing HA1-specific CD4+ T cell responses. Blood mDCs (LinHLA-
DR+CD11c+CD123) were sorted (purity > 98%). CD14+ monocytes and 
CD19+ B cells were purified by using StemCell enrichment kits. All work 
related to human subjects was in compliance with Institutional Review 
Board protocols approved by the Baylor Research Institute Review Board.
Monoclonal antibodies (mAbs) to lectins. Mouse mAbs specific for 
human DC-ASGPR, LOX-1, DC-SIGN, and Dectin-1 were generated as 
previously described (Rogers et al., 2005; Ni et al., 2010).
Other antibodies, reagents, and peptides. Fluorescent-labeled anti-CD3, 
anti-CD4, anti-CD11c, anti-CD14, anti-CD19, anti-CD123, anti-CTLA-4, 
anti-CD1c, anti-HLA-DR, anti-PD-1, and anti-Foxp3 antibodies were pur-
chased from BioLegend. Anti-IFN- and anti-IL-10 mAbs were purchased 
from BD. AntiLOX-1 mAb for immunofluorescent staining was pur-
chased from Abcam (MA). IL-10 (R&D Systems), anti-IL-10 (BIIR) and 
anti-IL-10R antibodies (R&D Systems) were used. Anti-CD16 (BD), anti-
CD32 (BD), and anti-CD64 (R&D Systems) antibodies were used. GM-
CSF, IL-4 and IFN- were purchased from the pharmacy at Baylor 
University Medical Center (TX). CFSE (Invitrogen), PD0325901 (Selleck 
Chemicals) and SB203580 (EMD) were used. Peptide libraries were pur-
chased from Mimotopes.
Recombinant mAbs and fusion proteins of antigens. Total RNA 
from hybridomas was used for cDNA synthesis and PCR amplification (BD) 
using the 5 primers provided by the kits and the Ig constant-specific 3 
primers as previously described (Rogers et al., 2005; Ni et al., 2010). For 
constructing the full-length chimeric antibodies, variable region-specific 
primers with flanking restriction sites were used to amplify DNA from either 
selected clonal TA plasmids or original cDNA. Enzyme-digested PCR frag-
ments were cloned into a modified pIRES2-DsRed2 vector (BD) with the 
constant-coding region of either mutated hIgG4H (S228P and L235E) or 
the wild-type hIgK that were previously engineered in the vector. The Flu 
HA1 fragment containing bp 52–993 of Influenza A virus (A/PR8/34, 
H1N1) hemagglutinin (gi/21693168/gb/AF389118.1/; with A619C and 
C959T changes) was engineered with a flanking NheI site followed by 
5-GATACAACAGAACCTGCAACACCTACAACACCTGTAACA-
ACA-3 at the 5 end and 6xHis tag coding sequence followed by stop co-
don and NotI site at the 3 end, which was fused downstream of and in-frame 
with the H chain coding region at the NheI site by NheI-Not I swamping. 
Stable CHO-S cells were made and grown in GlutaMAX and HT media 
(Invitrogen) and recombinant proteins were purified by protein A column 
chromatography. Similarly, recombinant antibody-PSA fusion proteins (rAb.
PSA) were encoded by inserting gi/34784812/ prostate-specific antigen resi-
dues 101–832 with proximal sequence 5-GCTAGCGATACAACAGA-
ACCTGCAACACCTACAACACCTGTAACAACACCGACAACAA-
CACTTCTAGCGC-3 (NheI site and Clostridium thermocellum CipA-derived 
spacer) and a distal NotI site into the same H chain vector. Recombinant 
antibody proteins were expressed in stable CHO-S transfectants and purified 
as described for hFc fusion proteins. Endotoxin levels were <0.2 U/ml.
CD4+ T cell responses. 5 × 103 IFNDCs loaded with 1–2 µg/ml recombi-
nant proteins were co-cultured with 2 × 105 CFSE-labeled CD4+ T cells. Cell 
proliferation was tested by measuring CFSE dilution on day 6. CD4+ T cells 
were restimulated with peptides for 6 h in the presence of brefeldin A (BFA) 
for staining IFN-, IL-2, IL-4, IL-5, and TNF. For IL-10, cells were activated 
with peptide for 18-24 h and BFA was added for the final 6–8 h of restimula-
tion. Cytokine levels in the culture supernatants were measured using the 
BeadLyte Luminex assay kit (Millipore) as per the manufacturer’s protocol. 
In suppression assays, effector cells were obtained by sorting Qtracker 565low 
CD4+ T cells (effectors) after 1 wk co-cultures of Qtracker 565 (InvivoGen)-
labeled autologous naive CD4+ T cells and IFNDCs loaded with recombinant 
fusion proteins. FACS-sorted effector cells were restained with Qtracker 565 
to separate them from responding cells, CFSE-labeled allogeneic naive CD4+ 
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